Analysis: White House Takes Bully Pulpit Approach On Drug Pricing Reform, Congress Unlikely To Act
Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk
Biotech Winners And Losers From Congress' Latest Funding Bill
Analyst: Why Diplomat Could Be Amazon's Ticket Into The Pharma Space